Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GigaGen Licenses ProteoNic\u2019s 2G UNicTM Technology Platform for High Yield Production of GigaGen\u2019s Mono- and Polyclonal Antibody Drug Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ProteoNic

    Menu

    ProteoNic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ProteoNic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic™ Technology

              Details:

              Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.

              Lead Product(s): Recombinant Polyclonal Antibody

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: GigaGen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProteoNic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

              Details:

              Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs including GIGA-2050.

              Lead Product(s): GIGA-2050

              Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: GigaGen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProteoNic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics

              Details:

              Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.

              Lead Product(s): Recombinant protein

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Immunomedics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY